Rx00142 - Levocarnitine


Name:
Levocarnitine
Rx ID:
Rx00142
Validation Level:
Phenomic Similarity:
0.515
Reference ID:
DB00583
Primary Indications:
Inborn error of metabolism; secondary carnitine deficiency; carnitine deficiency; end stage renal disease; dialysis
Orphan Indications:
No annotated orphan indications.
Rare Indications:
Carnitine deficiency; valproic acid toxicity; pediatric cardiomyopathy; zidovudine-induced mitochondrial myopathy
Common Indications:
Primary systemic carnitine deficiency; inborn error of metabolism; secondary carnitine deficiency; end stage renal disease; dialysis
Drug Interactions:
No annotated drug interactions in DrugBank.
Food Interactions:
No annotated food interactions in DrugBank.

Interactive 3D Model

Interactive Drug Target Network

Interactive Bipartite Drug Repurposing Graph

Rx00142
Primary Indication
Secondary Indication

Visualize Chemical Properties

Select x-axis

Select y-axis

Disease prevalence from Electronic Health Records

Click row to show all

Disease A Disease B A∩B A∩¬B B∩¬A Odds-Ratio P-Value Adjusted P-Value
end stage renal disease cardiomyopathy 1045 11565 13358 27.294 0 0.0
inborn error of metabolism cardiomyopathy 9671 325710 13358 8.969 0 0.0
carnitine deficiency inborn error of metabolism 53 53 325710 12.388 2.15E-31 6.89e-28

Shared Genetic Architectures of Disease Pairs

Click row to show all

Disease A Disease B Adjusted P-Value Shared Gene IDs
END STAGE RENAL DISEASE INBORN ERROR OF METABOLISM 1.99e-39 ABCA1, ABCB1, ABCC2, ABCC4, ABCC8, ABCG1, ABCG2, ABCG5, ABCG8, ACE, ADAM23, ADD1, ADIPOQ, ADRB1, ADRB2, ADRB3, AGT, AGTR1, AGXT, ALOX5, ALPL, APOA1, APOA5, APOB, APOC3, APOE, ARSA, ATF6, ATP7B, ATXN2, B2M, BCHE, BDKRB2, BHMT, BMP2, BMP4, BTBD9, CAPN10, CAT, CBS, CCL2, CCR2, CD163, CDKN2A, CDKN2B, CETP, CFH, COMT, CRP, CYP11B1, CYP11B2, CYP17A1, CYP1A1, CYP1A2, CYP2C19, CYP2C8, CYP2C9, CYP2D6, CYP2E1, CYP3A4, CYP3A5, CYP4F2, DPYD, EIF2AK1, ENOSF1, EPO, ESR1, ESR2, F2, F5, F7, FABP2, FGB, FMO3, FOLH1, GC, GCKR, GCSH, GLA, GNB3, GP1BA, GSTM1, GSTO1, GSTP1, GSTT1, HBB, HFE, HGF, HIF1A, HLA-A, HLA-B, HLA-C, HLA-DQA1, HLA-DRB1, HMOX1, HP, IFNG, IGF1R, IGF2, IKBKAP, IL10, IL12B, IL18, IL1A, IL1B, IL1RN, IL4, IL6, IL6R, IL8, IRS1, ITGB3, KDR, KIR2DL2, KIR2DL3, KIR2DS1, KIR2DS2, KIR2DS3, KIR3DL1, KIR3DS1, LDLR, LEPR, LIPC, LIPG, LMNA, LPL, LRP1, MBL2, MLH1, MON1A, MPO, MSH2, MTHFD1, MTHFR, MTR, MTRR, MTTP, NOS2, NOS3, NPC1L1, NPC2, NPPA, NR1H3, NR3C1, OGG1, PCSK9, PKD2, PLAT, PON1, PON2, POR, PPARA, PPARD, PPARG, PPARGC1A, PRKAG2, PTPRD, PVT1, RDBP, RFC1, RXRA, SCARB1, SELE, SERPINE1, SLC12A3, SLC13A3, SLC19A1, SLC22A1, SLC22A4, SLC22A5, SLC24A5, SLC2A1, SLC7A9, SLCO1A2, SLCO1B1, SLCO1B3, SMAD1, SMAD4, SMAD5, SOD2, SPP1, STC1, TCN2, TEK, TGFB1, TLR4, TLR9, TNF, TNFRSF11B, TNFRSF1B, TPMT, TPP1, TTR, TYMS, UBE2Q2, UCP2, UGT1A1, UMOD, VDR, VEGFA, XBP1
INBORN ERROR OF METABOLISM END STAGE RENAL DISEASE 1.99e-39 ABCA1, ABCB1, ABCC2, ABCC4, ABCC8, ABCG1, ABCG2, ABCG5, ABCG8, ACE, ADAM23, ADD1, ADIPOQ, ADRB1, ADRB2, ADRB3, AGT, AGTR1, AGXT, ALOX5, ALPL, APOA1, APOA5, APOB, APOC3, APOE, ARSA, ATF6, ATP7B, ATXN2, B2M, BCHE, BDKRB2, BHMT, BMP2, BMP4, BTBD9, CAPN10, CAT, CBS, CCL2, CCR2, CD163, CDKN2A, CDKN2B, CETP, CFH, COMT, CRP, CYP11B1, CYP11B2, CYP17A1, CYP1A1, CYP1A2, CYP2C19, CYP2C8, CYP2C9, CYP2D6, CYP2E1, CYP3A4, CYP3A5, CYP4F2, DPYD, EIF2AK1, ENOSF1, EPO, ESR1, ESR2, F2, F5, F7, FABP2, FGB, FMO3, FOLH1, GC, GCKR, GCSH, GLA, GNB3, GP1BA, GSTM1, GSTO1, GSTP1, GSTT1, HBB, HFE, HGF, HIF1A, HLA-A, HLA-B, HLA-C, HLA-DQA1, HLA-DRB1, HMOX1, HP, IFNG, IGF1R, IGF2, IKBKAP, IL10, IL12B, IL18, IL1A, IL1B, IL1RN, IL4, IL6, IL6R, IL8, IRS1, ITGB3, KDR, KIR2DL2, KIR2DL3, KIR2DS1, KIR2DS2, KIR2DS3, KIR3DL1, KIR3DS1, LDLR, LEPR, LIPC, LIPG, LMNA, LPL, LRP1, MBL2, MLH1, MON1A, MPO, MSH2, MTHFD1, MTHFR, MTR, MTRR, MTTP, NOS2, NOS3, NPC1L1, NPC2, NPPA, NR1H3, NR3C1, OGG1, PCSK9, PKD2, PLAT, PON1, PON2, POR, PPARA, PPARD, PPARG, PPARGC1A, PRKAG2, PTPRD, PVT1, RDBP, RFC1, RXRA, SCARB1, SELE, SERPINE1, SLC12A3, SLC13A3, SLC19A1, SLC22A1, SLC22A4, SLC22A5, SLC24A5, SLC2A1, SLC7A9, SLCO1A2, SLCO1B1, SLCO1B3, SMAD1, SMAD4, SMAD5, SOD2, SPP1, STC1, TCN2, TEK, TGFB1, TLR4, TLR9, TNF, TNFRSF11B, TNFRSF1B, TPMT, TPP1, TTR, TYMS, UBE2Q2, UCP2, UGT1A1, UMOD, VDR, VEGFA, XBP1

Chemical, Pharmacological and Biological Annotations


ATC Code:
A16AA01
Brands:
Albicar (Casasco); Aveptol (Leovan Pharmaceuticals); Biocarn (Medice); Bitobionil (S.J.A.); Cardimax (Integrated); Cardispan (Grossman); Carniben (Bennett Pharmaceuticals); Carnicor (Sigma Tau); Lecarna (Bennett Pharmaceuticals)
Categories:
Vitamin B Complex; Dietary Supplements
ChEBI ID:
16347
PubChem ID:
10917
KEGG Drug ID:
D02176
SMILE:
C[N+](C)(C)C[C@H](O)CC([O-])=O
InChI:
1S/C7H15NO3/c1-8(2,3)5-6(9)4-7(10)11/h6,9H,4-5H2,1-3H3/t6-/m1/s1
Classification:
Kingdom:
Organic Compounds
Superclass:
Organonitrogen Compounds
Class:
Quaternary Ammonium Salts
Subclass:
Carnitines
Indication:
For treatment of primary systemic carnitine deficiency, a genetic impairment of normal biosynthesis or utilization of levocarnitine from dietary sources, or for the treatment of secondary carnitine deficiency resulting from an inborn error ...
Click to show more...
Pharmacodynamics:
Levocarnitine is a carrier molecule in the transport of long chain fatty acids across the inner mitochondrial membrane. It also exports acyl groups from subcellular organelles and from cells to urine before they accumulate to toxic concentr...
Click to show more...
Description:
Constituent of striated muscle and liver. It is used therapeutically to stimulate gastric and pancreatic secretions and in the treatment of hyperlipoproteinemias. [PubChem]
Mechanism:
Levocarnitine can be synthesised within the body from the amino acids lysine or methionine. Vitamin C (ascorbic acid) is essential to the synthesis of carnitine. Levocarnitine is a carrier molecule in the transport of long chain fatty acids...
Click to show more...

Adsorption, Distribution, Metabolism, Excretion and Toxicity


Human Intestinal Absorption:
-
Blood Brain Barrier:
+
Caco-2 permeable:
+
P-glycoprotein substrate:
Non-substrate
P-glycoprotein inhibitor I:
Non-inhibitor
P-glycoprotein inhibitor II:
Non-inhibitor
Renal organic cation transporter:
Non-inhibitor
CYP450 2C9 substrate:
Non-inhibitor
CYP450 2D6 substrate:
Non-inhibitor
CYP450 2C19 substrate:
Non-inhibitor
CYP450 inhibitory promiscuity:
Low CYP Inhibitory Promiscuity
Ames test:
Non AMES toxic
Carcinogenicity:
Carcinogens
Biodegradation:
Ready biodegradable
Rat acute toxicity:
2.1624 LD50, mol/kg
hERG inhibition (predictor I):
Weak inhibitor
hERG inhibition (predictor II):
Non-inhibitor

Contact Us:
Please contact us if you have questions or comments about RepurposeDB. You can also contact us if you need help in submitting your drug repositioning investigation to RepurposeDB.


Dudley Laboratory
Department of Genetics and Genomic Sciences
Icahn Institute for Genomics and Multiscale Biology
Icahn School of Medicine at Mount Sinai
One Gustave L. Levy Place, Box 1498
Manhattan, New York City, NY
repurposedb@dudleylab.org